Zytiga (abiraterone acetate; Janssen Biotech) is available in a new 500mg strength tablet for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer. The new formulation was approved by the Food and Drug Administration (FDA) on April 17, 2017.
The drug labeling has been updated with dosage and administration information to reflect the new tablet strength. Zytiga tablets should be swallowed whole with water; they should not be crushed or chewed.
Zytiga, a CYP17 inhibitor, is converted to abiraterone which inhibits an enzyme expressed on testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. Androgen sensitive prostatic carcinoma responds to treatment that lowers androgen levels. Zytiga was shown to lower serum testosterone and other androgens in patients enrolled in a Phase 3 placebo-controlled trial.
The new 500mg strength film-coated tablets are available in 60-count bottles. Zytiga is also available as 250mg strength uncoated tablets in 120-count bottles.
For more information call (800) 526-7736 or visit ZytigaHCP.com.